{'52WeekChange': 0.061646104,
 'SandP52WeekChange': 0.0644362,
 'address1': '22 Cherry Hill Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 293.4,
 'askSize': 1200,
 'averageDailyVolume10Day': 359337,
 'averageVolume': 516180,
 'averageVolume10days': 359337,
 'beta': 0.933333,
 'beta3Year': None,
 'bid': 292.93,
 'bidSize': 1200,
 'bookValue': 23.672,
 'category': None,
 'circulatingSupply': None,
 'city': 'Danvers',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 294.87,
 'dayLow': 286.85,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.57,
 'enterpriseToEbitda': 47.343,
 'enterpriseToRevenue': 15.149,
 'enterpriseValue': 12738795520,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '978 777 8411',
 'fiftyDayAverage': 260.92087,
 'fiftyTwoWeekHigh': 301.11,
 'fiftyTwoWeekLow': 119.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 43935537,
 'forwardEps': 4.77,
 'forwardPE': 61.413,
 'fromCurrency': None,
 'fullTimeEmployees': 1536,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.020350002,
 'heldPercentInstitutions': 1.0137,
 'industry': 'Medical Devices',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1585612800,
 'lastMarket': None,
 'lastSplitDate': 970444800,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/abiomed.com',
 'longBusinessSummary': 'Abiomed, Inc. engages in the research, development, '
                        'and sale of medical devices to assist or replace the '
                        'pumping function of the failing heart. It also '
                        'provides a continuum of care to heart failure '
                        'patients. The company offers Impella 2.5 catheter, a '
                        'percutaneous micro heart pump with integrated motor '
                        'and sensors for use in interventional cardiology; and '
                        'Impella CP, a device used by interventional '
                        'cardiologists to support patients in the cath lab and '
                        'cardiac surgeons in the heart surgery suite. It also '
                        'provides Impella 5.0 and Impella LD, which are '
                        'percutaneous micro heart pumps with integrated motors '
                        'and sensors for use primarily in the heart surgery '
                        'suite; Impella RP, a percutaneous catheter-based '
                        'axial flow pump; Impella SmartAssist platform that '
                        'includes optical sensor technology for improved pump '
                        'positioning and the use of algorithms that enable '
                        'improved native heart assessment during the weaning '
                        'process; and Impella Connect, a cloud-based '
                        'technology that enables secure, cloud-based, and '
                        'remote viewing of the Automated Impella Controller '
                        'for physicians and hospital staffs. In addition, the '
                        'company engages in the development of Impella XR '
                        'Sheath, a sheath designed to expand and recoil to all '
                        'for ease of use upon insertion of an Impella heart '
                        'pump and minimize the size of the arteriotomy; '
                        'Impella BTR, a percutaneous micro heart pumps with '
                        'integrated motors and sensors; and Impella ECP pump '
                        'that is designed for blood flow of greater than three '
                        'liters per minute. It sells its products through '
                        'direct sales and clinical support personnel in the '
                        'United States, Canada, Europe, and Asia. The company '
                        'was founded in 1981 and is headquartered in Danvers, '
                        'Massachusetts.',
 'longName': 'Abiomed, Inc.',
 'market': 'us_market',
 'marketCap': 13195218944,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_247589',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 203008992,
 'nextFiscalYearEnd': 1648684800,
 'open': 293.2,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 3.66,
 'phone': '978 646 1400',
 'previousClose': 294.57,
 'priceHint': 2,
 'priceToBook': 12.374957,
 'priceToSalesTrailing12Months': 15.692099,
 'profitMargins': 0.24142,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 294.87,
 'regularMarketDayLow': 286.85,
 'regularMarketOpen': 293.2,
 'regularMarketPreviousClose': 294.57,
 'regularMarketPrice': 293.2,
 'regularMarketVolume': 184348,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45044100,
 'sharesPercentSharesOut': 0.0546,
 'sharesShort': 2458373,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2726854,
 'shortName': 'ABIOMED, Inc.',
 'shortPercentOfFloat': 0.0626,
 'shortRatio': 5.16,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ABMD',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 4.43,
 'trailingPE': 66.12641,
 'twoHundredDayAverage': 195.03928,
 'volume': 184348,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.abiomed.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01923'}